Percision Oncology is an unique approach to diagnosing, treating and monitoring cancer. View our latest technologies, team of doctors and more at Apollo Hospitals.
GlaxoSmithKline on Wednesday (April 13) said it had agreed to buy US group Sierra Oncology, a specialist in medicines for rare forms of cancer, for $1.9 billion.
The purchase, worth the equivalent of £1.6 billion, aims to support the development of new medicines alongside Sierra's bone marrow cancer treatment Momelotinib.
The deal, set to be completed this year, represents a near 40-percent premium to Sierra's closing share price on Tuesday, GSK said in a statement.
Momelotinib could help address the "significant unmet medical needs" of patients with the blood cancer myelofibrosis and anaemia, said GSK chief commercial officer
Luke Miels.
"With this proposed acquisition, we have the opportunity to potentially bring meaningful new benefits to patients and further strengthen our portfolio of specialty
medicines," he added.
Pharmaceutical giant AstraZeneca will acquire biotechnology company Neogene Therapeutics for up to $320 million, the London-listed drugmaker said on Tuesday
(November 29) as it seeks to build its pipeline of cell-based cancer treatments.
Though AstraZeneca's oncology portfolio accounted for more than a third of the company's revenue last year, it does not have an approved cell-based cancer therapy
and is behind rivals such as Novartis and Gilead.
"Neogene's leading (T-cell receptor) discovery capabilities and extensive manufacturing experience complement the cell therapy capability we have built over the
last three years," said Susan Galbraith, AstraZeneca's executive vice president of oncology research.
Cell-based treatments are a relatively new approach to treating cancer, most of which involve drawing the body's own immune cells and processing them in the lab to
target and kill cancer cells.
Neogene's approach goes one step further in that its experimental T-cell receptor therapies seek to target DNA mutations specific to tumours, not only certain
proteins on the surface of cancer cells.
AstraZeneca on Wednesday (April 5) said a combination of its cancer drugs Imfinzi and Lynparza met the main goal in a late-stage trial in patients with
advanced ovarian cancer.
The drugmaker said treatment with a combination of those drugs, along with chemotherapy and bevacizumab - the existing standard of care - improved progression-free
survival in newly diagnosed patients with advanced ovarian cancer without certain mutations.
Lynparza is jointly developed with U.S.-based Merck & Co as a treatment for breast cancer in early stage with certain mutations. Imfinzi alone, along with
chemotherapy and bevacizumab, did not reach statistical significance in its interim analysis, the drugmaker added.
Philipp Harter, director, Department of Gynaecology and Gynaecologic Oncology, Evangelische Kliniken Essen-Mitte, Germany and principal investigator for the trial,
said: "DUO-O showcases the power of academia and industry collaboration in advancing new treatment combinations for patients with ovarian cancer. I'm grateful for
the academic cooperative study groups and patients around the world that made this trial possible and look forward to sharing the results with the clinical community."
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "While there has been significant progress for patients with advanced ovarian cancer, an
unmet need still remains. These data from the DUO-O trial provide encouraging evidence for this this Lynparza and Imfinzi combination in patients without tumour
BRCA mutations and reinforce our continued commitment to finding new treatment approaches for these patients. It will be important to understand the key secondary
endpoints as well as data for relevant subgroups."
Aspire Pharma Limited has solidified its position as a leading specialty generics enterprise by adding leuprorelin acetate as a branded generic to its
oncology portfolio.
Leuprorelin acetate is hormone therapy recommended for patients with high-risk localised, locally advanced, and metastatic prostate cancer, serving as an
alternative to surgical castration for locally advanced cases.
Used as an alternative to surgical castration for locally advanced prostate cancer, a pre-filled syringe containing 11.25mg of leuprorelin acetate
(equivalent to 10.72 mg leuprorelin) is injected subcutaneously into the abdomen.
The British pharmaceutical company noted that one of its primary objectives is to seek "new investment opportunities" that brings products and companies into
its portfolio, aligning closely with Aspire values and therapeutic focus areas.
Prostate cancer is the most common cancer among men in the UK, with an average of over 52,000 men receiving a diagnosis of prostate cancer annually, as per
Prostate Cancer UK.
Aspire Pharma Limited has reaffirmed its commitment to combating prostate cancer by adding leuprorelin acetate as a branded generic to its oncology
portfolio. This move solidifies Aspire's position as a leading specialty generics enterprise.
Leuprorelin acetate is a hormone therapy recommended for patients with high-risk localized, locally advanced, and metastatic prostate cancer. It serves as an
alternative to surgical castration for locally advanced cases. A pre-filled syringe containing 11.25mg of leuprorelin acetate (equivalent to 10.72 mg leuprorelin)
is injected subcutaneously into the abdomen, providing a vital treatment option for patients.
Apollo Hospitals offer world class cancer treatment for medical & surgical oncology, skilfully performed by our highly trained oncologists who deliver best outcomes.
The oncologist is a specialized doctor who provides cancer or tumor treatments. There are multiple kinds of cancers and tumors for which specialized in the field doctors are required to provide the adequate treatment.
First open eHealth platform for Oncology
CANKADO (www.cankado.com) is the first open eHealth platform for oncology. Research and development teams are welcome to realize their projects on the basis of this platform. It is meant to support standard care and research projects as well as accompanying measures that serve the patients' well-being. Own ideas or concepts can be incorporated or realized on the basis of CANKADO.
Global pharmaceutical and biotechnology company AstraZeneca has signed an agreement with Scorpion Therapeutics to discover, develop and commercialize precision medicines against cancer proteins.
The collaboration, announced today (January 13), will focus on a class of proteins called transcription factors, which can regulate important cellular processes including cell growth and survival.
Many transcription factors have been identified earlier, but were considered 'undruggable' using conventional drug discovery approaches, the company said in a
statement.
Susan Galbraith, executive vice president, Oncology R&D, AstraZeneca, said: "Unlocking potentially transformative biology is pivotal for delivering the next wave of
cancer treatments.
"Scorpion's innovative platform is a strong strategic fit as we explore a range of new modalities across our broad drug discovery toolbox with promise to disrupt the activity of these highly-validated cancer targets."
Alphega Pharmacy Oncology Support Programme allows community pharmacists from six European countries to enhance support and guidance they provide to cancer
patients.
The programme aims to help upskill pharmacists and their teams to provide more expert advice to patients living with cancer, raising their profile in the community
as key healthcare providers.
Enhancing knowledge amongst community pharmacists about cancer treatment and its side effects is vital as cancer cases are set to increase if current trends continue.
The programme covers practical help topics, such as oral care, nutrition advice and skin, hair and nail care among others, helping patients to get more of the support
they need because community pharmacists are easily accessible, rather than needing to book a GP or consultant appointment.
With rates of cancer forecast to rise throughout Europe , and cancer patients likely on average to visit hospital less often, community pharmacists are well-placed to
look to support cancer patients with managing the side-effects of their treatment.
AstraZeneca said on Monday (June 27) two of its existing therapies were recommended for treating patients with some forms of high-risk breast cancers in the
European Union, in a boost to the company's oncology portfolio.
Lynparza, a cancer drug developed jointly with U.S.-based Merck, was backed for standalone use or in combination with endocrine therapy in adults with a form of
genetically mutated early-stage breast cancer.
The drug, which has received a similar recommendation in the United States in March, is a key asset for AstraZeneca. It was recommended in patients with low-to-normal
levels of a protein known as HER2 that is the target of several new therapies.
Enhertu - developed jointly with Japan's Daiichi Sankyo (4568.T) - was the other drug that was endorsed by the European Medicines Agency for treating an aggressive
form of breast cancer characterised by a high rate of HER2.
AstraZeneca said on Thursday (June 30) that a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with
an aggressive form of lung cancer, when given before surgery.
Data showed the combination was more effective in removing cancer cells in tissue samples taken during surgery when compared with just chemotherapy in patients with
non-small cell lung cancer, the drugmaker said.
The interim result is a boost to the company's oncology efforts - a major area of focus - following disappointing data for Imfinzi earlier in the year in another
area of therapy.
AstraZeneca added the trial would continue as planned to assess the additional main goal of event-free survival, and the interim data would be shared with health
authorities globally.
Imfinzi belongs to the immunotherapy class of treatments, which boost the body's defences to fight cancer by using antibodies that block or bind to foreign
substances in the body. The treatment generated $2.41 billion in 2021 sales.
PBR Staff Writer Published 22 April 2014 Swiss pharmaceutical firm Novartis has entered into a definitive agreement to acquire the oncology unit of Britain's GlaxoSmithKline (GSK) for about $14.5bn and up to $1.5bn contingent on a development milestone. As part of the deal, Novartis would have opt-in rights to GSK's current and future oncology R&D pipeline.
The market is broadly segmented into instruments, assays & kits, and services & software based on the basis of products & services. The assays & kits segment is expected to account for the largest share of the global POC molecular diagnostics market. This segment is also projected to register the highest CAGR during the forecast period.
Based on the applications, the market is segmented into respiratory diseases, hospital-acquired infections (HAIs), sexually transmitted diseases (STDs), oncology, hepatitis, and other applications (meningococcal meningitis, malaria, Herpes Simplex Virus, Ebola, Zika virus).
Buy Online Sorafenat 200mg tablet price in India, Sorafenat is a malignancy (chemotherapeutic) prescription.
Sorafenat, made by Natco, contains Sorafenib Tosylate as dynamic fixing.
It is a medicine oncology tranquilize that ought to be utilized underappropriate restorative direction and guidance.
We are leading suppliers & exporters of "Sorafenat 200Mg" in China, Russia, Hongkong, Bulgaria, Romania, India, Uk, USA. We're largest suppliers of Natco medicines & provide you the best price on Soafenat.
The lowest price sellers, suppliers, distributors & Exporters from Delhi. For more info please contact us
Buy Sorafenat 200Mg Tablet Suppliers Price in India
sorafenat-tablets-suppliers-india
Sorafenat 200Mg Tablets
Product Description:
Brand Name: Sorafenat
Generic Name: Sorafenib
Strength: 200mg
Package: Pack of 60 & 120 Tablets
Form: Tablets
Manufactured by: Natco Pharma Ltd
The Doctor's mostly prescribed Drug "Sorafenat 200Mg Tablet" twice in a day. It should be taken a couple of hours before taking your meal. You can gulp Sorafenat 200Mg Tablet down with the help of normal water, but be ensure you take it whole. Don't crush or break the tablet. Go for your regular blood pressure checks, when you are taking Sorafenat 200Mg Tablet. When it comes to storage of this drug, do not let it come in contact with heat or moisture.
Try not to convey the pharmaceutical to others, since they might experience the ill effects of an issue that is not adequately treated by this medication.
Sorafenat is an effective drug for treatment of cancer disease, The Sorafenat 200Mg Tablet is responsible for preventing , development & multiplication of cancer cells. And that is why this drug could be used in the treatment of the patients suffering from thyroid cancer, liver cancer or as well as renal cancer.
Buy Online Sorafenat 200 Mg Tablet Exporters Price India
sorafenat 200mg Suppliers price India
We are very thankful to come on this website "Sorafenat 200Mg S
Presently, In the US, around 12% of women develop breast cancer over the course of their lifetime. In Canada, an estimated 26,900 women were expected to be diagnosed with breast cancer in 2019 and breast cancer accounts for nearly 25% of new cases of cancer among Canadian women. Download complete report summary @
http://bit.ly/2vsEa1D
ImmunoGen has presented full data from the Phase III Forward I study of mirvetuximab soravtansine in ovarian cancer at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain, saying that it failed to meet the primary endpoint of progression-free survival (PFS).